Moreover, SSYX can activate endothelial nitric oxide synthase to release nitric oxide to protects endothelial cells (Jiang et al., 2021); reduce type I and type III collagens expression to inhibit myocardial fibrosis (Shen et al., 2014; Ma et al., 2018); and lowers the monocyte chemoattractant protein-1 and inflammatory factors like tumor necrosis factor-α and interleukin-6, exerting an anti-inflammatory effect (Zhang J. et al., 2023). The gene discussed is NOS3; the disease is Myocardial fibrosis.